ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Toward a Practical, Two-Step Process for Molnupiravir from Cytidine

preprint
submitted on 09.01.2021, 22:46 and posted on 11.01.2021, 12:03 by Dinesh J. Paymode, Natarajan Vasudevan, Saeed Ahmad, Appasaheb L. Kadam, Flavio S. P. Cardoso, Justina Burns, Daniel W. Cook, Rodger W. Stringham, David Snead

A two-step synthesis of molnupiravir (1) is presented. This work focuses on the development of practical reaction and purification conditions toward a manufacturing route. The sequence commences from highly available cytidine (2), and molnupiravir is formed through direct hydroxamination of the cytosine ring and esterification of the sugar’s primary alcohol without use of protecting or activating groups. A highly crystalline hydrate of N-hydroxycytidine (3) resulted in an easily purified intermediate, and a practical, off-the-shelf enzyme was selected for the acylation. The yield was increased through a chemically-promoted, selective ester cleavage which converted a by-product, molnupiravir isobutyryl oxime ester (4), into the final API. Both reactions proceed in >90% assay yield and crystallization procedures are used to afford intermediate and active pharmaceutical ingredient in purities above 99% with an overall yield of 60%. Excellent throughput and sustainability is achieved by limiting the total concentration to 7 volumes of solvent in the course of the two reactions with an overall PMI of 41 including work-up and isolation. Environmentally friendly solvents, water and 2-methyl tetrahydrofuran, enhance sustainability of the operation.

Funding

To reduce the API manufacturing cost for a wide range of global health drugs either in market or in development to improve patient access and enable uptake of critical GH medicines

Bill & Melinda Gates Foundation

Find out more...

History

Email Address of Submitting Author

drsnead@vcu.edu

Institution

Virginia Commonwealth University

Country

USA

ORCID For Submitting Author

0000-0003-1239-533X

Declaration of Conflict of Interest

No conflict of interest declared

Exports

ChemRxiv

Exports